First biosimilar monoclonal antibody filed in Europe
This article was originally published in Scrip
Executive Summary
An unnamed company has filed for approval of a biosimilar version of Johnson & Johnson/ Merck & Co 's immunosuppressant antibody, Remicade (infliximab), marking a much anticipated milestone in the history of biologic medicines.